0001415889-24-021370.txt : 20240815 0001415889-24-021370.hdr.sgml : 20240815 20240815165935 ACCESSION NUMBER: 0001415889-24-021370 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240813 FILED AS OF DATE: 20240815 DATE AS OF CHANGE: 20240815 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Torley Helen CENTRAL INDEX KEY: 0001528185 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32335 FILM NUMBER: 241213231 MAIL ADDRESS: STREET 1: C/O ONYX PHARMACEUTICALS, INC. STREET 2: 249 EAST GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HALOZYME THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001159036 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 880488686 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12390 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 794-8889 MAIL ADDRESS: STREET 1: 12390 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: HALOZYME THERAPEUTICS INC DATE OF NAME CHANGE: 20040312 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL YACHT SERVICES INC DATE OF NAME CHANGE: 20010912 4 1 form4-08152024_080831.xml X0508 4 2024-08-13 0001159036 HALOZYME THERAPEUTICS, INC. HALO 0001528185 Torley Helen C/O HALOZYME THERAPEUTICS, INC. 12390 EL CAMINO REAL SAN DIEGO CA 92130 true true false false PRESIDENT AND CEO 1 Common Stock 2024-08-13 4 M 0 10000 13.87 A 686744 D Common Stock 2024-08-13 4 S 0 10000 56.249 D 676744 D Common Stock 2024-08-14 4 M 0 10000 13.87 A 686744 D Common Stock 2024-08-14 4 S 0 3263 56.219 D 683481 D Common Stock 2024-08-14 4 S 0 6537 57.732 D 676944 D Common Stock 2024-08-14 4 S 0 200 58.17 D 676744 D Common Stock 2024-08-15 4 M 0 10000 13.87 A 686744 D Common Stock 2024-08-15 4 S 0 10000 57.949 D 676744 D Option to Purchase Common Stock 13.87 2024-08-13 4 M 0 10000 13.87 D 2025-02-06 Common Stock 10000 100000 D Option to Purchase Common Stock 13.87 2024-08-14 4 M 0 10000 13.87 D 2025-02-06 Common Stock 10000 90000 D Option to Purchase Common Stock 13.87 2024-08-15 4 M 0 10000 13.87 D 2025-02-06 Common Stock 10000 80000 D The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 22, 2024 in accordance with Rule 10b5-1. Represents a weighted average sales price per share. The shares were sold at prices ranging from $55.81 to $56.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $55.96 to $56.94. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $57.10 to $58.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $57.405 to $58.175. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 6, 2015. /s/ James R. Oehler, Attorney-in-Fact 2024-08-15